The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

EMA's CHMP has recommended AstraZeneca's Imfinzi for approval in the EU as a single agent for limited-stage small cell lung ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in ...

Imfinzi (durvalumab) has been cleared by the US regulator for the treatment of adult patients with locally advanced or metastatic BTC in combination with gemcitabine/cisplatin chemotherapy ...

AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), a pharmaceutical giant with a market capitalization of $215.44 billion and impressive gross profit margins of 82.61%, has received a recommendation for ...

The European Commission has cleared AZ's PD-L1 inhibitor Imfinzi (durvalumab) alongside PARP inhibitor Lynparza (olaparib) for patients with primary advanced or recurrent endometrial cancer with ...

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...